Efficacy and safety of recombinant human parathyroid hormone (1–84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study
Top Cited Papers
- 1 December 2013
- journal article
- research article
- Published by Elsevier BV in The Lancet Diabetes & Endocrinology
- Vol. 1 (4), 275-283
- https://doi.org/10.1016/s2213-8587(13)70106-2
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- CorrigendaJournal of Clinical Endocrinology & Metabolism, 2015
- Long-Term Follow-Up of Patients with HypoparathyroidismJournal of Clinical Endocrinology & Metabolism, 2012
- PTH replacement therapy of hypoparathyroidismOsteoporosis International, 2012
- Prevalence and progression of basal ganglia calcification and its pathogenic mechanism in patients with idiopathic hypoparathyroidismClinical Endocrinology, 2012
- Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future researchJournal of Bone and Mineral Research, 2011
- Long-Term Treatment of 12 Children with Chronic Hypoparathyroidism: A Randomized Trial Comparing Synthetic Human Parathyroid Hormone 1-34 versus Calcitriol and CalciumJournal of Clinical Endocrinology & Metabolism, 2010
- Effects of OnceVersusTwice-Daily Parathyroid Hormone 1–34 Therapy in Children with HypoparathyroidismJournal of Clinical Endocrinology & Metabolism, 2008
- HypoparathyroidismNew England Journal of Medicine, 2008
- Long-Term Treatment of Hypoparathyroidism: A Randomized Controlled Study Comparing Parathyroid Hormone-(1–34)VersusCalcitriol and CalciumJournal of Clinical Endocrinology & Metabolism, 2003
- A Randomized, Cross-Over Trial of Once-Daily Versus Twice-Daily Parathyroid Hormone 1-34 in Treatment of HypoparathyroidismJournal of Clinical Endocrinology & Metabolism, 1998